Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas. In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assesse...
Gespeichert in:
| Veröffentlicht in: | Clinical Sarcoma Research 2015-01, Vol.5 (1), p.4-4, Article 4 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4 |
|---|---|
| container_issue | 1 |
| container_start_page | 4 |
| container_title | Clinical Sarcoma Research |
| container_volume | 5 |
| creator | Poon, Vincent I Roth, Michael Piperdi, Sajida Geller, David Gill, Jonathan Rudzinski, Erin R Hawkins, Douglas S Gorlick, Richard |
| description | Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.
In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.
GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody. |
| doi_str_mv | 10.1186/s13569-014-0020-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4311500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541649853</galeid><sourcerecordid>A541649853</sourcerecordid><originalsourceid>FETCH-LOGICAL-b457t-d8a4d1bc1edd05dfb9135d6e2715da2e85eb146d7df0bdf5cc9cfea743585e473</originalsourceid><addsrcrecordid>eNp1Uk1P3DAQtVBRQbA_oBfkYy_Z-jubCxICukVC6qVwtRx7shgldmonbfn3NQqsQGptWWPNzHt682yEPlGypnSjvmTKpWoqQkVFCCNVc4COGRGy4pw1H97cj9Aq50dSliKyJvIjOmJSCcYZO0b3WxN2vY_ZO8DbK4bhz5ggZx8D9hkPxoepHHB4HksqgZ1TgmAB-4BHM3kIU8a__fSAY54gZpNsHMwpOuxMn2H1Ek_Q3dfrH5ffqtvv25vLi9uqFbKeKrcxwtHWUnCOSNe1TRnKKWA1lc4w2EhoqVCudh1pXSetbWwHphZclpKo-Qk6X3jHuR3A2aImmV6PyQ8mPelovH5fCf5B7-IvLTilkpBCcLUQtD7-h-B9pUynF-t1sV4_W6-bQvP5RUeKP2fIkx58ttD3JkCcs6ZKMsGV4qq0rpfWnelB-9DFwmvLdjB4GwN0vuQvpKBKNBvJC4AuAJtizgm6vTpK9PNX-Kees7e-7BGvD8__ApWfsiE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652436636</pqid></control><display><type>article</type><title>Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Poon, Vincent I ; Roth, Michael ; Piperdi, Sajida ; Geller, David ; Gill, Jonathan ; Rudzinski, Erin R ; Hawkins, Douglas S ; Gorlick, Richard</creator><creatorcontrib>Poon, Vincent I ; Roth, Michael ; Piperdi, Sajida ; Geller, David ; Gill, Jonathan ; Rudzinski, Erin R ; Hawkins, Douglas S ; Gorlick, Richard</creatorcontrib><description>Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.
In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.
GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.</description><identifier>ISSN: 2045-3329</identifier><identifier>EISSN: 2045-3329</identifier><identifier>DOI: 10.1186/s13569-014-0020-9</identifier><identifier>PMID: 25642322</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antibodies ; Care and treatment ; Diseases ; Gangliosides ; Genetic aspects ; Health aspects ; Immunohistochemistry ; Medical research ; Medicine, Experimental ; Osteosarcoma ; Patient outcomes ; Relapse ; Short Report ; Viral antibodies</subject><ispartof>Clinical Sarcoma Research, 2015-01, Vol.5 (1), p.4-4, Article 4</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Poon et al.; licensee BioMed Central. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b457t-d8a4d1bc1edd05dfb9135d6e2715da2e85eb146d7df0bdf5cc9cfea743585e473</citedby><cites>FETCH-LOGICAL-b457t-d8a4d1bc1edd05dfb9135d6e2715da2e85eb146d7df0bdf5cc9cfea743585e473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311500/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311500/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25642322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poon, Vincent I</creatorcontrib><creatorcontrib>Roth, Michael</creatorcontrib><creatorcontrib>Piperdi, Sajida</creatorcontrib><creatorcontrib>Geller, David</creatorcontrib><creatorcontrib>Gill, Jonathan</creatorcontrib><creatorcontrib>Rudzinski, Erin R</creatorcontrib><creatorcontrib>Hawkins, Douglas S</creatorcontrib><creatorcontrib>Gorlick, Richard</creatorcontrib><title>Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma</title><title>Clinical Sarcoma Research</title><addtitle>Clin Sarcoma Res</addtitle><description>Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.
In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.
GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.</description><subject>Antibodies</subject><subject>Care and treatment</subject><subject>Diseases</subject><subject>Gangliosides</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Immunohistochemistry</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Osteosarcoma</subject><subject>Patient outcomes</subject><subject>Relapse</subject><subject>Short Report</subject><subject>Viral antibodies</subject><issn>2045-3329</issn><issn>2045-3329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1Uk1P3DAQtVBRQbA_oBfkYy_Z-jubCxICukVC6qVwtRx7shgldmonbfn3NQqsQGptWWPNzHt682yEPlGypnSjvmTKpWoqQkVFCCNVc4COGRGy4pw1H97cj9Aq50dSliKyJvIjOmJSCcYZO0b3WxN2vY_ZO8DbK4bhz5ggZx8D9hkPxoepHHB4HksqgZ1TgmAB-4BHM3kIU8a__fSAY54gZpNsHMwpOuxMn2H1Ek_Q3dfrH5ffqtvv25vLi9uqFbKeKrcxwtHWUnCOSNe1TRnKKWA1lc4w2EhoqVCudh1pXSetbWwHphZclpKo-Qk6X3jHuR3A2aImmV6PyQ8mPelovH5fCf5B7-IvLTilkpBCcLUQtD7-h-B9pUynF-t1sV4_W6-bQvP5RUeKP2fIkx58ttD3JkCcs6ZKMsGV4qq0rpfWnelB-9DFwmvLdjB4GwN0vuQvpKBKNBvJC4AuAJtizgm6vTpK9PNX-Kees7e-7BGvD8__ApWfsiE</recordid><startdate>20150124</startdate><enddate>20150124</enddate><creator>Poon, Vincent I</creator><creator>Roth, Michael</creator><creator>Piperdi, Sajida</creator><creator>Geller, David</creator><creator>Gill, Jonathan</creator><creator>Rudzinski, Erin R</creator><creator>Hawkins, Douglas S</creator><creator>Gorlick, Richard</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150124</creationdate><title>Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma</title><author>Poon, Vincent I ; Roth, Michael ; Piperdi, Sajida ; Geller, David ; Gill, Jonathan ; Rudzinski, Erin R ; Hawkins, Douglas S ; Gorlick, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b457t-d8a4d1bc1edd05dfb9135d6e2715da2e85eb146d7df0bdf5cc9cfea743585e473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibodies</topic><topic>Care and treatment</topic><topic>Diseases</topic><topic>Gangliosides</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Immunohistochemistry</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Osteosarcoma</topic><topic>Patient outcomes</topic><topic>Relapse</topic><topic>Short Report</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poon, Vincent I</creatorcontrib><creatorcontrib>Roth, Michael</creatorcontrib><creatorcontrib>Piperdi, Sajida</creatorcontrib><creatorcontrib>Geller, David</creatorcontrib><creatorcontrib>Gill, Jonathan</creatorcontrib><creatorcontrib>Rudzinski, Erin R</creatorcontrib><creatorcontrib>Hawkins, Douglas S</creatorcontrib><creatorcontrib>Gorlick, Richard</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Sarcoma Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poon, Vincent I</au><au>Roth, Michael</au><au>Piperdi, Sajida</au><au>Geller, David</au><au>Gill, Jonathan</au><au>Rudzinski, Erin R</au><au>Hawkins, Douglas S</au><au>Gorlick, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma</atitle><jtitle>Clinical Sarcoma Research</jtitle><addtitle>Clin Sarcoma Res</addtitle><date>2015-01-24</date><risdate>2015</risdate><volume>5</volume><issue>1</issue><spage>4</spage><epage>4</epage><pages>4-4</pages><artnum>4</artnum><issn>2045-3329</issn><eissn>2045-3329</eissn><abstract>Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.
In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.
GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25642322</pmid><doi>10.1186/s13569-014-0020-9</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-3329 |
| ispartof | Clinical Sarcoma Research, 2015-01, Vol.5 (1), p.4-4, Article 4 |
| issn | 2045-3329 2045-3329 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4311500 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Antibodies Care and treatment Diseases Gangliosides Genetic aspects Health aspects Immunohistochemistry Medical research Medicine, Experimental Osteosarcoma Patient outcomes Relapse Short Report Viral antibodies |
| title | Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T20%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ganglioside%20GD2%20expression%20is%20maintained%20upon%20recurrence%20in%20patients%20with%20osteosarcoma&rft.jtitle=Clinical%20Sarcoma%20Research&rft.au=Poon,%20Vincent%20I&rft.date=2015-01-24&rft.volume=5&rft.issue=1&rft.spage=4&rft.epage=4&rft.pages=4-4&rft.artnum=4&rft.issn=2045-3329&rft.eissn=2045-3329&rft_id=info:doi/10.1186/s13569-014-0020-9&rft_dat=%3Cgale_pubme%3EA541649853%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652436636&rft_id=info:pmid/25642322&rft_galeid=A541649853&rfr_iscdi=true |